34P - The GATA3 and SENP5 network demonstrates control over breast cancer phenotypes

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Breast Cancer
Translational Research
Presenter Sol Efroni
Citation Annals of Oncology (2015) 26 (suppl_3): 10-14. 10.1093/annonc/mdv116
Authors S. Efroni, R. Ben-Hamo
  • Faculty Of Life Sciences, Bar-Ilan University, 52900 - Ramat Gan/IL

Abstract

Body

We have previously published our findings on the role of GATA3 and SENP5, as critical in different aspects of breast cancer [Breast Cancer Res. 2014 Nov 20;16(6):464 and Oncotarget. 2014 Feb 28;5(4):1071-82]. Following up on these findings, and under the assumption that modifications to the molecular network surrounding ER are of critical importance in different types of breast cancer, we now report studies into core changes within this network. Using a set of computational tools we developed [Bioinformatics. 2014 Sep 1;30(17):2399-405.; PLoS Comput Biol. 2013;9(11):e1003351] we identified specific changes within the SENP5, GATA3, ER and NCL network. These network modifications display the difference between tumor and normal breast samples; at the Herceptin response network and at the Tamoxifen response network. The network analyses identifies, for example, specific association between GATA3 and STAT1, with a specific type of presentation in Tamoxifen responding patients, and of a different type in non responders. Similarly, NCL loses parts of its regulation in Herceptin responders compared with non responders. The complete set of findings is beyond the scope of this text. We believe that the careful consideration of this emerging network may shed new light on patient stratification, may lead to improved stratification approaches and to improved directed treatment.

Disclosure: All authors have declared no conflicts of interest.